Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus MD 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus MD 50.
HYPAQUE-CYSTO vs MD-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
300 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent